GENinCode Partners with Sohin Genetics to Distribute Heart Disease Risk Test in Mexico

An announcement from GENinCode UK Ltd. ( (GB:GENI) ) is now available.

GENinCode has announced a collaboration with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® test, a polygenic risk score for predicting and preventing coronary heart disease. This partnership aims to expand GENinCode’s reach in the Mexican market, where cardiovascular disease is a significant health concern, and to enhance the identification and prevention of heart disease through personalized treatment strategies, potentially reducing severe cardiovascular events and associated healthcare costs.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £3.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

Spark’s Take on GB:GENI Stock

According to Spark, TipRanks’ AI Analyst, GB:GENI is a Neutral.

GENinCode UK Ltd. faces significant financial challenges, with persistent losses and negative cash flows weighing heavily on its overall score. However, recent strategic partnerships and regulatory approvals provide a positive outlook for market expansion and product adoption, partially offsetting financial concerns. Technical indicators suggest moderate bullish momentum, but valuation remains a concern due to negative earnings.

To see Spark’s full report on GB:GENI stock, click here.

More about GENinCode UK Ltd.

GENinCode Plc is an Oxford-based predictive genetics company focused on the prevention of cardiovascular disease and risk assessment of ovarian cancer. The company specializes in genetic risk prediction and prevention, offering products like the CARDIO inCode-Score® test to assess inherited genetic risks for heart disease.

Average Trading Volume: 1,072,103

Technical Sentiment Signal: Sell

Current Market Cap: £8.03M

For an in-depth examination of GENI stock, go to TipRanks’ Overview page.